Filing Analysis
Telomir Pharmaceuticals announced the publication of a peer-reviewed preclinical study in the Journal of Oncology Research and Therapy regarding its lead compound, Telomir-Zn. The study demonstrates the compound's ability to inhibit histone demethylases and suppress tumor growth in prostate and triple-negative breast cancer (TNBC) models.
📋 Key Facts
- Publication titled 'Telomir-Zn Modulates Intracellular Iron and Copper to Inhibit JmjC Histone Demethylases and Suppress Tumor Growth in Prostate and Triple-Negative Breast Cancer' appeared in Journal of Oncology Research and Therapy, Vol 11, Issue 3.
- Preclinical data shows Telomir-Zn reduces primary tumor growth in prostate cancer models.
- The compound demonstrated the ability to reduce metastatic dissemination in an HCC1806 TNBC model.
- Study suggests synergistic effects when combined with paclitaxel in TNBC models.
Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for Telomir-Zn in the journal Biomedicine & Pharmacotherapy. The study demonstrated dose-dependent improvements in glucose homeostasis and insulin resistance using a zebrafish model of Type 2 diabetes.
📋 Key Facts
- Publication title: 'Telomir-Zn Restores Glucose Homeostasis and Reduces Insulin Resistance in a Diet-Induced Zebrafish Model of Type 2 Diabetes'
- Study showed improvements in fasting blood glucose, glucose tolerance, fasting insulin levels, and HOMA-IR
- This is the company's second peer-reviewed publication in 2026
- Telomir-Zn has already received FDA IND clearance for Phase 1/2 clinical trials (TELO-001) for advanced or metastatic triple-negative breast cancer
Telomir Pharmaceuticals announced the departure of CFO Alan Weichselbaum and the appointment of Andriy Mushak as Fractional CFO effective June 6, 2026. Mr. Mushak is a partner at LMAM Consulting Group, LLC, and will provide services via a consulting agreement.
🚩 Red Flags
- Transition from a full-time CFO to a 'Fractional' CFO may indicate budget constraints or a lack of stability in the financial leadership role.
📋 Key Facts
- Alan Weichselbaum ceased serving as CFO effective June 6, 2026.
- Andriy Mushak appointed as Fractional CFO effective June 6, 2026.
- Mr. Mushak is a CPA and Partner at LMAM Consulting Group, LLC.
- The Company will pay Mr. Mushak $6,000 per month for his services under a Consulting Agreement with LMAM.
- The departure of Mr. Weichselbaum was not due to any disagreement with the Company.
Telomir Pharmaceuticals announced the publication of a peer-reviewed preclinical study on its compound Telomir-1 (Telomir-Zn) in the journal Advances in Redox Research. The study demonstrated positive therapeutic effects of Telomir-1 in cellular systems and a zebrafish model of Wilson's disease.
📋 Key Facts
- Published a peer-reviewed preclinical study on Telomir-1 in the journal Advances in Redox Research on May 20, 2026.
- The study evaluated Telomir-1 (Telomir-Zn) in cellular systems and an ATP7B-deficient zebrafish model of Wilson's disease.
- Findings showed reductions in oxidative stress signaling, hepatic copper accumulation, liver injury biomarkers, and improvements in survival outcomes.
Telomir Pharmaceuticals received FDA clearance for its Investigational New Drug (IND) application for Telomir-Zn to treat triple-negative breast cancer. The company plans to initiate a Phase 1/2 clinical trial in the first half of 2026.
📋 Key Facts
- FDA cleared the IND application for lead product candidate Telomir-Zn on April 24, 2026.
- The target indication is advanced or metastatic triple-negative breast cancer (TNBC).
- The planned Phase 1/2 trial will enroll approximately 76 patients.
- The trial will be conducted at a leading U.S. academic medical center.
- Primary endpoint for the Phase 2 portion is Objective Response Rate (ORR).
Telomir Pharmaceuticals completed the acquisition of TELI Pharmaceuticals to consolidate global rights for its lead drug candidate, Telomir-1. The transaction involved the issuance of over 34 million restricted shares and includes a $1 million immediate cash contribution from Bayshore Trust.
🚩 Red Flags
- Massive equity dilution: The issuance of 34,389,710 shares is likely a very large percentage of the total shares outstanding for a micro-cap company.
- Valuation risk: The exchange ratio was based on third-party valuations of private and public entities, which can be highly subjective in early-stage biotech.
- Concentration of control: Significant share issuance to a specific group (TELI shareholders) and the involvement of Bayshore Trust.
📋 Key Facts
- Acquisition of 100% of TELI Pharmaceuticals completed on April 22, 2026.
- Issued 34,389,710 restricted shares of common stock as consideration to TELI shareholders.
- Consolidates global rights for Telomir-1 (Telomir-Zn), eliminating previous geographic fragmentation between North American and international markets.
- Bayshore Trust contributed $1 million in cash at closing as a condition of the deal.
- Bayshore Trust entered a Commitment Agreement to potentially pay up to $4 million more upon FDA IND acceptance and Phase 1/2 clinical study initiation.
Telomir Pharmaceuticals, Inc. has regained compliance with Nasdaq Listing Rule 5620(a) following the completion of its 2025 Annual Meeting of Shareholders. Nasdaq has officially closed the matter, resolving the previous deficiency regarding shareholder meeting requirements.
🚩 Red Flags
- The company was previously non-compliant with Nasdaq rules, indicating a past failure to meet basic corporate governance requirements (holding an annual meeting).
📋 Key Facts
- Received a compliance letter from Nasdaq Capital Markets on March 30, 2026.
- The company is now in compliance with Nasdaq Listing Rule 5620(a).
- Compliance was achieved by holding the 2025 Annual Meeting of Shareholders.
- Nasdaq has determined the matter is now closed and the company remains listed on The Nasdaq Stock Market LLC.
Telomir Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for Telomir-1 (Telomir-Zn) to treat advanced and metastatic Triple-Negative Breast Cancer (TNBC). The company plans to initiate a Phase 1/2 clinical trial evaluating the drug as an oral monotherapy upon FDA clearance.
📋 Key Facts
- IND application submitted to the FDA on March 31, 2026.
- Target indication is advanced and metastatic Triple-Negative Breast Cancer (TNBC).
- Telomir-1 (Telomir-Zn) is a small-molecule epigenetic therapy targeting iron-dependent pathways.
- Planned Phase 1/2 trial will use a 3+3 dose-escalation design followed by a Simon two-stage design for Phase 2.
- Preclinical GLP safety studies reported no treatment-related adverse or dose-limiting toxicities.
- The company intends to present data at the AACR Annual Meeting 2026.
Telomir Pharmaceuticals received shareholder approval for the acquisition of Teli Pharmaceuticals and a significant expansion of its equity incentive plan. The company also amended its bylaws to reduce the quorum requirement for shareholder meetings to one-third and authorized the repricing of underwater stock options.
🚩 Red Flags
- Significant potential dilution from the 5,000,000 share increase in the incentive plan (approx. 14.5% of total outstanding shares).
- The introduction of option repricing allows management to lower exercise prices if the stock price drops, which is often viewed as shareholder-unfriendly.
- Reducing the quorum requirement to one-third makes it easier for a minority of shareholders to pass significant corporate actions.
- The acquisition of Teli Pharmaceuticals involves a share issuance exceeding 20% of the current outstanding stock.
📋 Key Facts
- Shareholders approved the acquisition of Teli Pharmaceuticals, Inc., involving the issuance of more than 20% of outstanding common stock.
- The 2023 Omnibus Incentive Plan was amended to increase reserved shares from 6,500,000 to 11,500,000.
- The amended Incentive Plan now allows for the repricing of options or stock appreciation rights (SARs) at the administrator's discretion.
- Bylaws were amended to reduce the quorum requirement for shareholder actions to one-third (33.3%).
- As of the January 23, 2026 record date, there were 34,380,971 shares of common stock outstanding.
- Salberg & Company, P.A. was ratified as the independent auditor for the fiscal year ending December 31, 2025.
Telomir Pharmaceuticals announced positive preclinical in vitro data for its investigational compound Telomir-Zn, showing tumor cell mortality in multiple human triple-negative breast cancer (TNBC) models. The company confirmed the mechanism is iron-dependent and reiterated plans to submit an IND application in Q1 2026.
📋 Key Facts
- Telomir-Zn showed near-complete tumor cell mortality in MDA-MB-468 (Basal-A / EGFR-high) models at 72 hours.
- Significant partial reduction in viable cells observed in HCC70 and MDA-MB-231 lines at 72 hours.
- Iron-rescue experiments confirm the mechanism of action is mechanistically driven by iron modulation, not nonspecific cytotoxicity.
- The company plans to submit an Investigational New Drug (IND) application in Q1 2026.
- Prior GLP safety/toxicology studies in rats and dogs showed no treatment-related adverse toxicity.
Telomir Pharmaceuticals reported positive preclinical cellular data for its lead compound, Telomir-Zn, demonstrating a mechanism that modulates intracellular zinc and iron levels to potentially address cancer and aging. The company also announced plans to submit an Investigational New Drug (IND) application in Q1 2026.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Preclinical studies with Smart Assays Biotechnologies show Telomir-Zn induces rapid intracellular redistribution of metals (increased zinc, decreased labile ferrous iron).
- The effect is dose-dependent and occurs within ~30 minutes without affecting cell viability.
- Mechanism targets oxidative stress, mitochondrial dysfunction, and DNA methylation instability.
- Company plans to submit an IND application in the first quarter of 2026.
- Manuscript submissions for completed studies have been initiated.
Telomir Pharmaceuticals received a notice from Nasdaq stating it is non-compliant with Rule 5620(a) due to failure to hold an annual meeting of shareholders within the required timeframe. The company must submit a compliance plan by February 23, 2026.
🚩 Red Flags
- Delisting notice (Nasdaq Rule 5620(a) non-compliance)
- Regulatory delay: SEC review of proxy statement has prevented the company from meeting mandatory shareholder meeting deadlines.
- Potential for future delisting if a compliance plan is not accepted or implemented.
📋 Key Facts
- Received written notice from Nasdaq on January 8, 2026.
- Non-compliance is due to violation of Nasdaq Listing Rule 5620(a) regarding the timing of the annual meeting of shareholders.
- The delay is attributed to the SEC's ongoing review of the company's preliminary proxy statement submitted on November 20, 2025.
- Deadline to submit a compliance plan to Nasdaq is February 23, 2026.
- The notice does not result in immediate delisting or impact current trading on the Nasdaq Capital Market.
Telomir Pharmaceuticals announced positive preclinical efficacy results for its lead candidate, Telomir-1 (Zn-Telomir), in zebrafish models of triple-negative breast cancer (TNBC). The study demonstrated significant reductions in tumor growth and metastasis in specific TNBC subtypes, providing guidance for future clinical trial design.
🚩 Red Flags
- The results were not effective in one of the three models (the treatment-resistant model representing 15-25% of cases).
📋 Key Facts
- Preclinical efficacy study conducted using BioReperia's ZTX® ONCOLEADS platform in zebrafish tumor xenograft models.
- Telomir-1 showed statistically significant reductions in primary tumor growth and cancer cell spread in two out of three TNBC models tested.
- In one chemo-resistant model, Telomir-1 was effective as both a monotherapy and in combination with paclitaxel.
- The responsive models represent approximately 40–60% of TNBC cases, while the non-responsive model represents 15–25%.
- Company is currently continuing IND-enabling activities.
Telomir Pharmaceuticals announced significant compensation adjustments and incentive awards for CEO Erez Aminov, including a $400,000 short-term incentive and a contingent award tied to the potential acquisition of TELI Pharmaceuticals.
🚩 Red Flags
- Significant contingent compensation tied to an acquisition (3% of deal value) creates potential conflict of interest for the CEO regarding the terms of the TELI acquisition.
- The IND milestone incentive is linked to a regulatory event that has not yet occurred, potentially incentivizing aggressive filing strategies.
📋 Key Facts
- Approved 2025 Short-Term Incentive (STI) payout of $400,000 for CEO Erez Aminov based on 2025 performance.
- Approved a contingent milestone incentive of $150,000 payable upon FDA acceptance of the Telomir-1 IND submission.
- Approved a transaction advisory award for the potential acquisition of TELI Pharmaceuticals equal to 3% of the total transaction value.
- CEO base salary increased to $500,000 effective January 1, 2026.
- The transaction advisory award may be delivered in cash, equity, or a combination thereof.
Telomir Pharmaceuticals announced favorable results from its IND-enabling GLP toxicology and safety pharmacology studies for its lead candidate, Telomir-1. The data supports the company's plan to submit an IND application in Q1 2026.
📋 Key Facts
- Completed GLP toxicology and safety pharmacology studies for Telomir-1 (Zn-Telomir) using rat and dog models.
- No treatment-related adverse or dose-limiting toxicities were observed across cardiovascular, respiratory, phototoxicity, and repeat-dose studies.
- Non-rodent studies showed no test-article-related changes in blood pressure, heart rate, ECG parameters, or body temperature.
- Company anticipates submitting an Investigational New Drug (IND) application in Q1 2026.
- First-in-human clinical studies are targeted for the first half of 2026.
Telomir Pharmaceuticals reported positive preclinical data for its lead compound, Telomir-1, showing a dose-related reduction in PSA levels in human prostate cancer cells. The company also highlighted successful tumor volume reductions in mouse models when used as a single agent or in combination with paclitaxel.
📋 Key Facts
- In vitro study in LNCaP (androgen-responsive human prostate cancer cells) showed Telomir-1 reduces PSA levels in a dose-related manner.
- Telomir-1 was associated with reductions in cellular energy metabolism and viability in the same study.
- Preclinical mouse model (PC3 xenograft) data shows Telomir-1 reduced tumor volume as a single agent.
- Combination of Telomir-1 and paclitaxel resulted in full reduction of tumor volume with no treatment-related mortality, whereas paclitaxel alone showed high mortality.
- Company is advancing regulatory IND-enabling activities for upcoming IND submission.
Telomir Pharmaceuticals, Inc. announced the resignation of Craig Eagle from its Board of Directors, effective November 14, 2025.
🚩 Red Flags
- None identified; the filing explicitly states there were no disagreements regarding the departure.
📋 Key Facts
- Craig Eagle resigned as a member of the Board of Directors on November 14, 2025.
- The resignation was effective immediately.
- The company stated the resignation was not due to any disagreement with management or the Board.
Telomir Pharmaceuticals announced positive in vitro findings where its investigational compound, Telomir-1, demonstrated dose-dependent cell death in aggressive human leukemia (HL60) cells. This expands the company's preclinical oncology profile beyond breast, pancreatic, and prostate cancer models.
🚩 Red Flags
- Preclinical stage company: Findings are in vitro (cell culture) and do not guarantee clinical success in humans.
📋 Key Facts
- Telomir-1 showed a clear, dose-dependent reduction in HL60 leukemia cell viability in vitro.
- The compound demonstrated an ability to reduce intracellular Fe²⁺ levels more effectively than Deferoxamine (DFO) in prior studies.
- Research indicates Telomir-1 inhibits three major families of lysin histone-demethylase (KDM2, KDM5, and KDM6) enzymes.
- The compound has previously shown activity against triple-negative breast, pancreatic, and aggressive prostate cancer models.
Telomir Pharmaceuticals reported positive preclinical data showing its lead compound, Telomir-1, significantly outperforms the FDA-approved iron chelator Deferoxamine (DFO) in reducing intracellular iron levels in human cell lines. The study utilized live-cell imaging to demonstrate superior cellular penetration and dose-dependent activity.
📋 Key Facts
- Telomir-1 demonstrated a strong, dose-dependent reduction of intracellular Fe²⁺ in HaCaT (human keratinocyte) cells.
- The compound's performance significantly exceeded that of the gold-standard FDA-approved chelator Deferoxamine (DFO) at equivalent concentrations.
- Data was obtained using FerroOrange, a fluorescent probe for detecting ferrous iron in living cells.
- The company is also developing Telomir-Zn, which combines iron/copper binding with zinc delivery to support antioxidant defense.
Telomir Pharmaceuticals reported positive preclinical data for its investigational compound, Telomir-1, in an aggressive prostate cancer model. The study suggests the compound may reset 'kill-and-clean' defense systems by reducing DNA methylation of CASP8 and GSTP1 genes.
📋 Key Facts
- Preclinical study conducted in mice bearing human aggressive prostate cancer tumors.
- Telomir-1 treatment showed a progressive and sustained decrease in DNA methylation of CASP8 and GSTP1 through Day 21.
- Telomir-1 combined with chemotherapy showed lower DNA methylation levels than chemotherapy alone, suggesting potentiation of epigenetic effects.
- In comparison to Rapamycin (mTOR inhibitor), Telomir-1 demonstrated a more sustained effect on gene methylation by Day 21.
Telomir Pharmaceuticals has entered into a binding Letter of Intent (LOI) to acquire TELI Pharmaceuticals via a stock-for-stock exchange. The deal aims to consolidate worldwide IP rights for the lead candidate, Telomir-1, and includes up to $5 million in potential cash contributions from TELI shareholders.
🚩 Red Flags
- Dilution risk: The stock-for-stock exchange and the issuance of shares corresponding to milestone payments will result in significant dilution for existing Telomir shareholders.
- Valuation uncertainty: The exchange ratio is not yet determined and relies on a third-party valuation, creating ambiguity regarding the impact on share price.
📋 Key Facts
- Transaction structure: Stock-for-stock exchange of all outstanding TELI shares for Telomir common stock.
- Exchange ratio to be determined by an independent third-party valuation.
- Cash infusion component: Up to $5 million in total cash contributions from TELI shareholders ($1M at closing, $2M upon FDA IND acceptance, and $2M upon Phase 1/2 study initiation).
- Strategic goal: Unification of U.S. and ex-U.S. rights for Telomir-1 (an oral epigenetic therapy) into a single public entity.
- Lockup provision: Six-month lockup period on shares issued to TELI shareholders.
Telomir Pharmaceuticals announced new preclinical laboratory findings showing that its lead compound, Telomir-1, reduces the viability of aggressive human pancreatic cancer cells in vitro. This data complements previous successful results in triple-negative breast and prostate cancer models.
🚩 Red Flags
- Preclinical data is highly speculative and does not guarantee clinical success or FDA approval.
📋 Key Facts
- Telomir-1 demonstrated a concentration-dependent decrease in PANC-1 (pancreatic cancer) cell viability and mitochondrial activity in vitro.
- The effect was partially reversed by iron re-addition, suggesting an iron-dependent metabolic mechanism.
- The compound targets pathways involving tumor suppressor genes like MASPIN, RASSF1A, STAT1, KDM2B, and KDM6B.
- Company plans to expand research into leukemia models and initiate in vivo validation studies as part of IND preparation.
Telomir Pharmaceuticals announced positive preclinical laboratory findings for its lead compound, Telomir-1, demonstrating selective toxicity in aggressive triple-negative breast cancer (TNBC) cells. The study suggests the compound disrupts iron-dependent energy pathways and mitochondrial function in cancer cells.
🚩 Red Flags
- Preclinical stage: The results are based on laboratory/in vitro studies and have not yet been tested in humans.
📋 Key Facts
- Preclinical studies show Telomir-1 produces a concentration-dependent reduction in TNBC cell survival.
- The mechanism of action appears linked to cellular iron regulation; adding iron back to the system allowed cancer cells to recover.
- Telomir-1 targets epigenetic mechanisms, specifically influencing Jumonji domain histone demethylases (KDMs) like KDM5A/B and KDM6B.
- The company plans to expand studies to pancreatic and leukemia models.
- Next steps include further animal studies in preparation for an Investigational New Drug (IND) submission.
Telomir Pharmaceuticals announced positive preclinical findings for its lead compound, Telomir-1, showing it can reset DNA methylation of tumor suppressor genes (MASPIN and RASSF1A) in aggressive prostate cancer models. The results suggest potential efficacy in combating metastasis and treatment resistance.
📋 Key Facts
- Preclinical studies showed Telomir-1 restores MASPIN activity by reversing chemotherapy-induced DNA hypermethylation.
- Telomir-1 reduced RASSF1A methylation in a dose-dependent manner, with enhanced effects when combined with chemotherapy.
- The compound targets mechanisms linked to metastasis and treatment resistance in aggressive prostate cancer models.
- The company is currently advancing Telomir-1 through IND-enabling studies.
Telomir Pharmaceuticals announced new in vitro data for its lead candidate, Telomir-1, demonstrating potent inhibition of the KDM5 histone demethylase family. This expands the drug's known pharmacological profile to include DNA methylation and multiple histone demethylase families (KDM2/KDM6), suggesting a broad-spectrum epigenetic mechanism.
📋 Key Facts
- New in vitro studies by Eurofins Discovery show Telomir-1 inhibits three members of the KDM5 histone demethylase family.
- Telomir-1 previously demonstrated activity against UTX (KDM6A), JMJD3 (KDM6B), FBXL10 (KDM2B), and FBXL11 (KDM2A).
- The drug showed ability to reactivate tumor suppressors such as CDKN2A and STAT1 in prostate cancer models.
- Telomir-1 reportedly spares broad acetyltransferases like GCN5L2, potentially reducing systemic toxicity.
- Company is currently advancing IND-enabling studies and GMP scale-up for Telomir-1.
Telomir Pharmaceuticals announced positive preclinical data for its lead candidate, Telomir-1, showing it can reactivate the CDKN2A tumor suppressor gene in aggressive human prostate cancer models. The results indicate that Telomir-1 outperformed both Rapamycin and chemotherapy in inhibiting DNA hypermethylation in these models.
🚩 Red Flags
- None identified in this filing; the report focuses on positive preclinical developments.
📋 Key Facts
- Preclinical data shows Telomir-1 inhibits DNA hypermethylation of the CDKN2A master tumor suppressor gene.
- In vivo human prostate cancer models (PC3 xenografts) showed Telomir-1 outperformed Rapamycin and chemotherapy.
- The mechanism involves resetting epigenetic silencing, building on previous STAT1 reactivation data.
- Company is currently scaling up CMC activities toward GMP production for IND-enabling studies.
Telomir Pharmaceuticals, Inc. completed a block sale of 1,550,000 common shares to institutional investors via its at-the-market (ATM) offering facility. The sale was executed at an average price of $1.87 per share, generating approximately $2.9 million in gross proceeds.
🚩 Red Flags
- Equity dilution for existing shareholders due to the issuance of 1.55 million new shares.
📋 Key Facts
- Completed sale of 1,550,000 shares of common stock on August 28, 2025.
- Average price per share: $1.87 (noted as a premium to the prior day's close).
- Total gross proceeds: approximately $2.9 million.
- Offering facilitated through Rodman & Renshaw via the StockBlock platform.
- The offering did not include any warrants.
Telomir Pharmaceuticals announced positive in vitro data for its lead drug candidate, Telomir-1, demonstrating dual action in targeting DNA methylation pathways and Wnt/Tankyrase signaling. The data suggests potential efficacy in treating cancer, aging, and age-related diseases with a potentially favorable safety profile due to enzyme selectivity.
🚩 Red Flags
- Company is in the preclinical stage, meaning no human clinical trial data has been reported to validate these findings.
📋 Key Facts
- In vitro studies conducted by Eurofins Discovery showed Telomir-1 potently inhibits UTX (KDM6A), a histone demethylase.
- Telomir-1 demonstrated inhibition of epigenetic enzymes FBXL10, FBXL11, and JMJD3.
- The drug candidate showed no activity against GCN5L2 (KAT2A), potentially reducing toxicity risks compared to other epigenetic drugs.
- Data indicated low-level inhibitory activity against Tankyrases (PARP5A and PARP5B) without the telomere shortening associated with potent inhibitors.
- Previous in vivo data showed Telomir-1 could reactivate silenced tumor suppressors STAT1 and TMS1.
Telomir Pharmaceuticals announced new in vitro data for its lead drug candidate, Telomir-1, demonstrating the inhibition of three key histone demethylase enzymes (JMJD3, FBXL10, and FBXL11). This mechanism suggests potential applications across oncology, autoimmune diseases, neurodegeneration, and metabolic disorders.
📋 Key Facts
- In vitro data from Eurofins Discovery shows Telomir-1 inhibits JMJD3, FBXL10, and FBXL11 enzymes.
- The drug candidate targets epigenetic modulation to restore normal gene expression patterns.
- Previous data showed Telomir-1 reactivated STAT1 and TMS1 tumor suppressor genes in prostate cancer models more effectively than Paclitaxel or Rapamycin.
- Company is currently preparing for IND-enabling studies for Telomir-1.
Telomir Pharmaceuticals reported positive preclinical results for its lead compound, Telomir-1, demonstrating improved mitochondrial energy production and reduced oxidative stress in Progeria human fibroblast cell lines. The study indicates the compound restores energy without inducing unwanted cell proliferation.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Lead compound 'Telomir-1' showed increased mitochondrial energy production (WST-1 assay) in HGPS patient cells.
- Demonstrated reduction of reactive oxygen species (ROS) under basal and induced stress conditions.
- Calcein assay confirmed no increase in live cell number, indicating no stimulation of cell proliferation.
- The study was conducted in collaboration with Smart Assays Biotechnologies Ltd.
- Company is currently completing IND-enabling studies for Telomir-1.
Telomir Pharmaceuticals, Inc. completed a block sale of 1,100,000 common shares via its at-the-market (ATM) equity offering facility on July 18, 2025.
🚩 Red Flags
- Use of ATM offerings can indicate a need for immediate liquidity, often seen in micro-cap biotech companies with high burn rates.
📋 Key Facts
- Sold 1,100,000 shares of common stock in block sales to institutional investors.
- Average sale price was $2.6045 per share.
- Gross proceeds totaled approximately $2.9 million (before fees and expenses).
- The offering was executed through an at-the-market (ATM) facility via Rodman & Renshaw/StockBlock platform.
- The sale price represented a premium to the prior day's closing price.
Telomir Pharmaceuticals reported positive preclinical data for its lead candidate, Telomir-1, demonstrating the ability to reverse epigenetic gene silencing of STAT1 and TMS1 in prostate cancer models. The results showed superior epigenetic modulation compared to Paclitaxel and Rapamycin without affecting telomere length.
📋 Key Facts
- Preclinical study used a murine xenograft model with PC3 human prostate cancer cells.
- Telomir-1 demonstrated dose-dependent reversal of STAT1 hypermethylation via DNA methylation over 21 days of oral administration.
- Telomir-1 showed full reversal of STAT1 silencing, outperforming Paclitaxel (no reversal) and Rapamycin (partial demethylation).
- The compound also reduced hypermethylation of TMS1 (ASC/PYCARD), a pro-apoptotic tumor suppressor.
- Data indicated no measurable elongation of telomeres in PC3 tumor tissue following administration.
- Company is evaluating Telomir-1 for oncology, Wilson’s disease, AMD, autism, and dysphonia.
Telomir Pharmaceuticals announced positive preclinical data for its lead candidate, Telomir-1, showing cellular protective activity in human progeria cell lines. The results demonstrated increased cell viability and normalized oxidative stress/mitochondrial function in HGPS cells.
📋 Key Facts
- Preclinical study conducted by SmartAssays using human progeria (HGPS) cells from The Progeria Research Foundation.
- Telomir-1 showed significant increase in cell viability under basal and toxic metal conditions.
- Study demonstrated normalization of Reactive Oxygen Species (ROS) and reversal of calcium overload/mitochondrial damage.
- Company is finalizing IND-enabling studies and plans to engage with the FDA regarding regulatory pathways and orphan drug designation.
Telomir Pharmaceuticals announced positive preclinical data for its lead candidate, Telomir-1, in a zebrafish model of Wilson's disease. The study showed dose-dependent improvements in neurological, liver, and kidney functions.
📋 Key Facts
- Lead candidate: Telomir-1 (small molecule).
- Preclinical results in ATP7B C271X -/- zebrafish model show 4- to 5-fold reduction in episodic tremor events.
- Observed ~50% reduction in copper accumulation in dry liver tissue.
- Normalization of ALT, AST, and bilirubin levels to near wild-type levels.
- Company aims for IND submission by year-end 2025.
- Human clinical trials are planned for the first half of 2026.
Telomir Pharmaceuticals announced positive preclinical data for its lead compound, Telomir-1, in an animal model of Werner Syndrome. The study demonstrated significant biological age reversal markers, including restored DNA methylation and increased telomere length.
🚩 Red Flags
- Preclinical data only; results have not yet been validated in human clinical trials.
📋 Key Facts
- Preclinical study conducted on a validated animal model of Werner Syndrome (WS).
- Telomir-1 showed restoration of healthy DNA methylation at two CpG island regions.
- Observed increase in telomere length exceeding levels in healthy controls.
- Full reversal of muscle and body weight loss in the disease model.
- 50% reduction in oxidative stress markers reported.
- 100% survival rate in treated animals vs. 15% mortality in untreated controls.
Telomir Pharmaceuticals announced its participation in the BIO International Convention 2025 to pursue strategic partnerships and M&A. The company also provided clinical updates on its lead candidate, Telomir-1, including preclinical progress in age reversal, diabetes, and cancer models.
📋 Key Facts
- Company will participate in BIO International Convention (June 16–19, 2025) for partnering and M&A discussions.
- Telomir-1 is preparing for an IND submission by year-end 2025.
- First-in-human clinical trials for Telomir-1 are anticipated in H1 2026.
- Preclinical data shows Telomir-1 reduced tumor growth by ~50% in a prostate cancer model when used as monotherapy.
- Telomir-1 demonstrated strong binding affinity for copper ions in vitro.
- The company is targeting orphan indications including Werner’s syndrome, Wilson’s disease, Progeria, and dysphonia.
Telomir Pharmaceuticals announced positive preclinical data for its oral small molecule candidate, Telomir-1, in a zebrafish model of Age-Related Macular Degeneration (AMD). The study demonstrated functional vision improvement, retinal structural restoration, and reduced oxidative stress.
📋 Key Facts
- Study utilized the Sen57wrn-/-ND6-/+ zebrafish model mimicking dry AMD and geographic atrophy.
- Telomir-1 was administered orally for 14 days to 18-month-old animals.
- Observed functional vision improvement in central vision response and motion detection.
- Histological analysis showed regeneration of retinal layers (INL, GCL, IPL, OPL) and increased layer thickness.
- Reactive oxygen species (ROS) levels were reduced by up to 50%.
- Zero mortality observed in the treated group compared to a 15% mortality rate in untreated animals.
- Endpoints used are consistent with FDA-recognized surrogate markers for visual function.
Telomir Pharmaceuticals, Inc. announced the mutual separation of CFO Michelle Yanez and the appointment of Alan Weichselbaum as the new Chief Financial Officer, effective May 15-16, 2025.
🚩 Red Flags
- Sudden departure of the CFO (even if stated as mutual) can sometimes signal internal transitions or shifts in financial strategy.
📋 Key Facts
- Michelle Yanez resigned as CFO, Treasurer, and Secretary effective May 16, 2025; resignation was mutual and not due to disagreements.
- Alan Weichselbaum appointed as CFO effective May 15, 2025.
- Weichselbaum's compensation includes an annual salary of $60,000 and up to 50,000 stock options vesting over 6 and 12 months.
- New CFO has extensive background as a CPA, MBA, and former CEO of a boutique brokerage firm.
Telomir Pharmaceuticals raised $3 million through a direct equity sale of 1 million restricted common shares at $3.00 per share to The Bayshore Trust, an affiliate of the company's largest shareholder. The transaction was executed at an 18% premium to the previous day's closing price and contains no warrants or convertible features.
🚩 Red Flags
- Related-party transaction: The investor (The Bayshore Trust) is an affiliate of the company's largest shareholder.
- Reliance on a single large stakeholder for multiple funding rounds ($3M in May 2025, $1M in Dec 2024).
📋 Key Facts
- Raised $3 million in straight equity financing on May 19, 2025.
- Issued 1 million restricted common shares at a price of $3.00 per share.
- Transaction represents an 18% premium over the closing price of $2.54 (as of May 19, 2025).
- Investor is The Bayshore Trust, an entity affiliated with the Company's largest shareholder.
- The deal includes no warrants, no discounts, and no convertible features.
- Proceeds are earmarked for regulatory activities and the planned IND submission for Telomir-1.
Telomir Pharmaceuticals announced the successful preclinical validation of Telomir-Ag2, a novel antimicrobial drug candidate based on its proprietary Telomir-1 platform. The candidate demonstrated broad-spectrum activity against resistant bacterial strains in recent studies.
📋 Key Facts
- Identification of Telomir-Ag2 as a novel drug candidate using the proprietary Telomir-1 platform.
- Preclinical MIC study showed broad-spectrum antibacterial activity against Gram-positive and Gram-negative strains.
- Demonstrated efficacy against methicillin- and aminoglycoside-resistant Staphylococcus aureus (MARSA).
- Telomir-Ag2 outperformed the company's previous Silver(I)-based formulation, Telomir-Ag1.
- The technology focuses on stabilizing Silver(II) in a biologically compatible form to leverage its high oxidative potential.
Telomir Pharmaceuticals announced positive preclinical in vitro data for its lead drug candidate, Telomir-1. The studies demonstrate the compound's ability to reverse key drivers of cellular decline, including improved mitochondrial activity and reduced oxidative stress.
📋 Key Facts
- Preclinical data shows Telomir-1 reverses hallmarks of cellular decline in human cell lines.
- Key findings include improved cell viability under stress and boosted mitochondrial function.
- Data demonstrates reduction in reactive oxygen species (ROS) and restoration of calcium signaling.
- The compound showed protection against metal-induced toxicity (iron and copper).
- Research is being expanded into autism spectrum disorder (ASD) and spasmodic dysphonia (SD).
Telomir Pharmaceuticals announced positive preclinical results for its lead compound, Telomir-1, in a highly aggressive human prostate cancer animal model. The data suggests the drug reduces tumor size by ~50% and mitigates chemotherapy toxicity.
🚩 Red Flags
- Preclinical data is early-stage and does not guarantee clinical success in humans.
📋 Key Facts
- Preclinical findings show Telomir-1 reduced tumor size by approximately 50% in an aggressive human prostate cancer animal model.
- Telomir-1 demonstrated suppression of tumor development rather than promotion, addressing a key safety concern for telomere-elongating drugs.
- Combination therapy with Paclitaxel showed no mortality in animals, whereas Paclitaxel alone resulted in significant weight loss and 33% mortality.
- The study utilized highly aggressive human prostate cancer cells.
Telomir Pharmaceuticals announced positive preclinical study results for its lead compound, Telomir-1. The data suggests the compound reverses calcium dysregulation and oxidative stress in human cell lines (HaCaT and ARPE-19).
🚩 Red Flags
- The filing contains only preclinical data (cell line studies), which does not guarantee success in human clinical trials.
📋 Key Facts
- Preclinical findings show Telomir-1 reduces intracellular calcium overload in HaCaT and ARPE-19 cell lines.
- The study indicates Telomir-1 mitigates oxidative stress and supports cellular integrity under extreme stress conditions.
- Telomir-1 is being positioned as a potential first-in-class therapy for neurodegenerative disorders, retinal diseases, and metabolic dysfunction.
- Company is advancing toward human clinical trials.
Telomir Pharmaceuticals announced a scientific breakthrough regarding the stabilization of Silver(I) and Silver(II) ions using their proprietary Telomir-1 molecule. The company claims this development could unlock significant markets in antimicrobial treatments, wound care, and medical coatings.
🚩 Red Flags
- No immediate financial impact or revenue mentioned; the news is purely scientific/preclinical in nature.
- The filing lacks specific data, clinical trial results, or quantitative metrics to support the 'breakthrough' claim.
📋 Key Facts
- Achieved successful capture and stabilization of both Silver(I) (Ag⁺) and highly reactive Silver(II) (Ag²⁺) in a biologically compatible form using Telomir-1.
- The breakthrough addresses the historical instability of Silver(II), which has previously prevented its medical application.
- Potential applications include advanced antimicrobial treatments, wound care solutions, and infection-resistant medical coatings.
- The company intends to continue advancing preclinical research and exploring regulatory pathways for Silver(II)-complexed Telomir-1.
Telomir Pharmaceuticals announced positive preclinical study results for its lead compound, Telomir-1. The study demonstrated the compound's ability to significantly reduce oxidative stress in human retinal cell lines caused by copper and iron exposure.
📋 Key Facts
- Preclinical study evaluated Telomir-1 in human retinal cell lines.
- Telomir-1 significantly reduced Reactive Oxygen Species (ROS) elevation caused by copper and iron exposure.
- The compound demonstrated ROS regulation properties at low concentrations, suggesting a regulatory effect rather than simple metal chelation.
- Company is initiating AMD (Age-Related Macular Degeneration) disease models to evaluate in vivo efficacy.
Telomir Pharmaceuticals announced positive preclinical results for its lead compound, Telomir-1, demonstrating the ability to reverse oxidative stress in human cell lines. The company is also exploring the drug's potential application in treating avian influenza and other viral infections.
🚩 Red Flags
- Results are preclinical (human cell lines) and have not yet been validated in human clinical trials.
📋 Key Facts
- Preclinical studies in human cell lines showed Telomir-1 can fully reverse copper-induced elevation of Reactive Oxygen Species (ROS).
- The compound provided robust cellular protection against copper toxicity while maintaining cellular integrity.
- Telomir-1 demonstrated efficacy at doses significantly lower than copper levels, suggesting a mechanism beyond simple chelation.
- Company is exploring applications for avian influenza (bird flu) and other viruses.
Telomir Pharmaceuticals announced positive preclinical results for its candidate Telomir-1, demonstrating lifespan restoration in a C. elegans model of progeria (Werner Syndrome mimic). The findings suggest potential efficacy in addressing cellular aging processes.
🚩 Red Flags
- Preclinical data only; results in nematodes do not guarantee success in human clinical trials.
📋 Key Facts
- Preclinical study conducted on nematodes (C. elegans) with wrn-1 gene mutation.
- Telomir-1 restored lifespan to near-normal levels in the mutated model.
- The target condition is progeria, a rare genetic disorder causing rapid aging.
- Findings focus on cellular issues associated with accelerated aging.
Telomir Pharmaceuticals announced positive preclinical findings for its lead compound, Telomir-1, demonstrating strong copper-binding properties. The company is targeting Wilson's disease as a primary indication and plans to submit IND applications by Q4 2025.
📋 Key Facts
- Preclinical studies of Telomir-1 demonstrate significant copper-binding capabilities.
- The compound shows potential for treating Wilson’s disease (a rare genetic disorder involving copper accumulation).
- Company aims to submit Investigational New Drug (IND) and INAD applications by Q4 2025.
- Clinical trials are tentatively planned for 2026.
Telomir Pharmaceuticals, Inc. announced the resignation of its independent auditor, Cherry Bekaert LLP, and the subsequent engagement of Salberg & Company P.A. as its new auditor for the fiscal year ending December 31, 2024.
🚩 Red Flags
- Auditor change combined with a prior 'going concern' qualification in previous audit reports.
- Reported material weaknesses in internal control over financial reporting for the 2022 and 2023 fiscal years.
- The presence of an explanatory paragraph regarding going concern indicates significant liquidity or operational risk.
📋 Key Facts
- Cherry Bekaert LLP resigned as the company's independent registered public accounting firm effective December 16, 2024.
- The previous auditor issued an explanatory paragraph regarding the Company's ability to continue as a going concern for fiscal years 2023 and 2022.
- Cherry Bekaert reported material weaknesses in internal control over financial reporting as of December 30, 2023, and 2022.
- Salberg & Company P.A. was engaged on December 18, 2024, to serve as the new independent auditor for fiscal year 2024.
- The company stated there were no disagreements with Cherry Bekaert regarding accounting principles or auditing scope.
Telomir Pharmaceuticals, Inc. raised $1 million through the issuance of 142,857 shares of restricted common stock at $7 per share. The transaction was completed at a 20% premium to the closing price and did not include warrants.
🚩 Red Flags
- Issuance of restricted common stock often indicates a private placement with limited liquidity for the purchaser initially.
- The need for capital raises (even at a premium) is typical for micro-cap biotech but highlights ongoing cash burn requirements.
📋 Key Facts
- Raised $1,000,000 via issuance of 142,857 shares of common stock.
- Share price set at $7.00 per share.
- Transaction represents a 20% premium to the closing price on December 9, 2024.
- The offering was for restricted common stock under Section 4(a)(2) exemption.
- No warrants were issued as part of this transaction.
- The investor had previously extended a $5 million non-dilutive line of credit to the company earlier in 2024, which remains undrawn.
Telomir Pharmaceuticals announced positive preclinical study results for its molecule, Telomir-1, in a zebrafish model of Type 2 diabetes. The study demonstrated the ability to reverse insulin resistance and normalize blood glucose levels by targeting iron metabolism.
📋 Key Facts
- Preclinical study conducted in collaboration with Pentagrit using a zebrafish model of Type 2 diabetes mellitus.
- Telomir-1 showed dose-dependent normalization of blood glucose levels and improved oral glucose tolerance.
- Results indicated significant reduction in HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) values.
- The molecule's mechanism of action targets iron metabolism to address oxidative stress and beta-cell damage.
- Study results showed increased survival rates in the treated models.
Telomir Pharmaceuticals, Inc. announced the immediate resignation of Michael Jerman from his roles on the Board of Directors and as Chair of the Audit Committee effective November 18, 2024. The company has appointed Dr. Matthew Del Giudice to the Audit Committee and Matthew Pratt Whalen as its new Chairman.
🚩 Red Flags
- Immediate resignation of an Audit Committee Chair can sometimes signal internal friction, though the filing explicitly denies any disagreement.
📋 Key Facts
- Michael Jerman resigned from the Board and the Audit Committee on November 18, 2024.
- The resignation is stated to be due to a desire to pursue other activities, not due to any disagreement with the Company.
- Dr. Matthew Del Giudice was appointed to the Audit Committee on November 20, 2024.
- Matthew Pratt Whalen was appointed as the new Chairman of the Audit Committee on November 20, 2024.
Telomir Pharmaceuticals announced positive preclinical results for its compound Telomir-1, demonstrating age reversal and increased lifespan in C. elegans model organisms using microfluidic technology. The company is now expanding research into progeria models and potential studies on elderly dogs.
📋 Key Facts
- Preclinical study conducted with Nagi Biosciences SA used in vivo microfluidic-based assays.
- Study subjects: Caenorhabditis elegans (nematode) model organisms.
- Key outcomes reported: enhanced mobility in older organisms, measurable reversal of biological age markers, and statistically significant increase in lifespan.
- The company is engaging with the Progeria Foundation to test Telomir-1 on human progeria cell lines.
- Planned in vivo study using a progeria C. elegans model.
- Ongoing discussions with North Carolina State College of Veterinary Medicine regarding studies on elderly dogs with osteoarthritis.
Telomir Pharmaceuticals entered into a $5 million unsecured promissory note agreement with The Starwood Trust, a related-party trust established by the Company's founder. The facility allows for flexible capital access at a 7% interest rate without equity dilution.
🚩 Red Flags
- Related-party transaction involving the company founder.
📋 Key Facts
- Agreement date: September 24, 2024.
- Counterparty: The Starwood Trust (a related-party trust established by the Company's founder).
- Facility amount: Up to $5,000,000 in unsecured loan advances.
- Interest rate: 7% per annum (simple interest).
- Maturity date: September 24, 2026.
- Terms: Non-convertible; no warrants issued; non-dilutive to common stock.
- Status: No advances have been requested as of the filing date.
Telomir Pharmaceuticals has appointed Dr. Itzchak Angel as Chief Scientific Advisor via a consulting agreement effective August 28, 2024. Dr. Angel will lead the company's IND and INAD application processes for its lead candidate, Telomir-1.
🚩 Red Flags
- The appointment is through a consulting agreement rather than a full-time executive role (though common in micro-cap biotech).
📋 Key Facts
- Dr. Itzchak Angel appointed as Chief Scientific Advisor effective August 28, 2024.
- Appointment is via a consulting agreement with Angel Pharmaceutical Consulting & Technologies Ltd.
- Dr. Angel previously served as Head of Pharmacology at Synthelabo (now Sanofi-Aventis).
- Focus of role: Guiding IND (human) and INAD (veterinary) submissions for Telomir-1.
- Telomir-1 is a small molecule designed to lengthen DNA's telomere caps, targeting conditions like progeria.
Telomir Pharmaceuticals announced the departure of CFO Nathan Fuentes and the simultaneous appointment of Michelle Yanez as the new Chief Financial Officer, effective June 18, 2024.
🚩 Red Flags
- Sudden departure of a C-suite officer (CFO) can sometimes signal internal friction, though the filing explicitly states no disagreement exists.
- The separation agreement includes a non-disparagement clause and monetary compensation for the departing officer.
📋 Key Facts
- Nathan Fuentes resigned as CFO on June 18, 2024, via a mutual separation agreement.
- The Company will pay Mr. Fuentes an aggregate of $62,500 in equal installments over three months.
- Michelle Yanez, MBA, appointed as CFO; she previously served as the Company's part-time Corporate Controller since May 2022.
- Ms. Yanez's base salary is set at $137,500 per year.
- The resignation of Mr. Fuentes was not due to any disagreement regarding Company operations, policies, or practices.
Telomir Pharmaceuticals, Inc. provided a presentation at the National Press Club regarding its preclinical data and clinical study plans. This is a non-material disclosure under Item 7.01 intended to provide updates on company development.
📋 Key Facts
- Presentation delivered on April 15, 2024, at the National Press Club in Washington, D.C.
- Content focused on recent preclinical data and upcoming preclinical/clinical study plans.
- The filing is made under Item 7.01 (Regulation FD Disclosure) and does not constitute 'filed' information for liability purposes under Section 18.
Telomir Pharmaceuticals, Inc. announced the immediate resignation of Christos Nicholoudis from his roles as General Counsel and a member of the Board of Directors on April 10, 2024.
🚩 Red Flags
- Immediate departure of both General Counsel and a Board member can sometimes signal internal friction, though the filing explicitly states no disagreement exists.
📋 Key Facts
- Christos Nicholoudis resigned as General Counsel effective immediately on April 10, 2024.
- Mr. Nicholoudis also resigned from his position on the Board of Directors.
- The resignation was due to a desire to pursue other activities and not due to any disagreement with the Company.
Telomir Pharmaceuticals, Inc. completed a public offering of 1,000,000 shares of common stock at $7.00 per share, raising approximately $7 million in gross proceeds. The offering included an over-allotment option for the underwriters and the issuance of representative warrants.
🚩 Red Flags
- Issuance of representative warrants to underwriters can lead to future dilution.
📋 Key Facts
- Public offering of 1,000,000 shares of common stock at $7.00 per share.
- Gross proceeds totaled $7,000,000 before underwriting discounts and expenses.
- Underwriting agreement includes a 45-day option for underwriters to purchase up to an additional 150,000 shares.
- Kingswood Investments received warrants to purchase 50,000 shares of common stock at an exercise price of $7.00.
- Lock-up agreements were established for 180 days (or 365 days for initial holders) following the offering.
- The company is an emerging growth company.